Effects of oral iron supplementation on the gut microbiome and plasma uremic toxin levels in patients with chronic kidney disease - Effect of oral iron on gut-derived uremic toxin levels in CKD

aboratoriumgeneeskunde0 个研究点目标入组 6 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Age range: 18-80 years
•2. CKD stage III-IV (GFR of 15-60 ml/min /1.73m2)
•3. Iron deficient and an indication for treatment with ferrous fumarate, that is Hb < 7 mmol/L, TSAT (transferrin saturation) <20% and ferritin < 200 µg/l, in the presence of a CRP < 10 mg/L).
•4. Living in the region of Nijmegen, that is within 20 km from Radboudumc

•1. Patients already under treatment with iron (orally or intravenously), or finished iron treatment <= 4 weeks before start of the trial.
•2. Patients using over the counter iron supplements / iron fortified products
•3. Constipation (defecation less than 3 times a week).
•4. Treatment with antibiotics <= 4 weeks before start the trial. If antibiotic treatment is required during the trial, patients are excluded from the trial.
•5. Start of Sevelamer treatment during the trial (patients already on Sevelamer treatment and which is continued do not have to be excluded).
•6. Hb < 4.5

发起方

aboratoriumgeneeskunde